



# AMCP Daily Dose®



In affiliation with  
**BulletinHealthcare**

Good morning, Betty Whitaker  
July 26, 2021

## Leading the News

Advertisement

LAUREL ROAD HIGH YIELD SAVINGS<sup>SM</sup>

**EARN 10X  
THE NATIONAL AVERAGE**

Annual Percentage Yield (APY)

laurel road FOR DOCTORS [LEARN MORE](#)

Laurel Road is a brand of KeyBank N.A. Member FDIC

### Biden Administration Buys 200M More Doses Of Pfizer/BioNTech's COVID-19 Vaccine

[Reuters](#) (7/23, Mishra, Erman) reported Pfizer “and German partner BioNTech said on Friday the U.S. government has purchased 200 million additional doses of their COVID-19 vaccine to help with pediatric vaccination as well as possible booster shots – if they are needed.” An official from the Biden Administration “with knowledge of the contract said that as part of the agreement, Pfizer will provide the United States with 65 million doses intended for children under 12, including doses available immediately after the vaccine is authorized” by the FDA for use in that age group.

The [Wall Street Journal](#) (7/23, Hopkins, Subscription Publication) reported the vaccine makers plan to deliver 110 million of the additional doses by year’s end and the remainder by April 2022.

Also reporting was [CBS News](#) (7/23, Perry).

## From AMCP

### Mark Your Calendar for These Upcoming Webinars

Stay on top of the latest developments in managed care pharmacy by attending a live webinar. Take a look at the schedule and register today:

**Tuesday, July 27, 2021, 2-3pm ET**  
**FreeStyle Libre 2 System: Transforming Diabetes Care Through Life-Changing Technology**

*A Science & Innovation Webinar sponsored, developed and presented by a sponsor.*

[AMCP Members and Non-Members - Free](#)



**Thursday, Aug. 5, 2021, 2-3pm ET****An Investigational Drug for CKD-associated Pruritus in HD Patients**

A Pre-approval Information Exchange (PIE) Webinar sponsored, developed and presented by a sponsor.

[AMCP Members and Non-Members \(Payers/HCDMs Only\) - Free](#)

**Thursday, Aug. 26, 2021, 2-3pm ET****Eosinophilic Esophagitis: New Treatments on the Horizon**

This educational activity is supported by an unrestricted educational grant.

This live program is accredited for 1.0 contact hours for pharmacists.

[AMCP Members and Non-Members - Free](#)

Follow us on social: [@amcporg](#)

[AMCP Event Calendar](#)

## Research

### Scientists Complete Human Genome

The [New York Times](#) (7/23, Zimmer) says that two decades following the revealing of “the draft sequence of the human genome,” a group of 99 scientists has deciphered the whole thing. The Times adds, “The consortium has posted six papers online in recent weeks in which they describe the full genome.” The data, which scientific journals are currently reviewing, will provide scientists with a more profound “understanding of how DNA influences risks of disease, the scientists say, and how cells keep it in neatly organized chromosomes instead of molecular tangles.”

### Japanese Drugmaker Launches Human Trials For Once-A-Day Pill For Treating COVID-19

The [Wall Street Journal](#) (7/25, Landers, Subscription Publication) reports Japanese drugmaker Shionogi has launched human trials of the first once-a-day pill for patients with COVID-19. The Japanese company is months behind Pfizer and Merck & Co., which have pills for treating COVID-19 in later-stage tests.

Advertisement

### Israeli Data Suggest Effectiveness Of Pfizer COVID-19 Vaccine Has Diminished Since Winter

According to the [New York Times](#) (7/23, Zimmer), the Israeli “health ministry reported on Thursday that although effectiveness of the Pfizer-BioNTech vaccine remains high against severe illness, its protection against infection by the coronavirus may have diminished significantly compared with this winter and early spring.” Based on an analysis of the “government’s national health statistics, researchers estimated that the Pfizer shot was just 39 percent effective against preventing infection in the country in late June and early July, compared with 95 percent from January to early April.”

However, the vaccine remains “more than 90 percent effective in preventing severe disease.”

Also reporting was [The Hill](#) (7/24, Castronuovo).

### Drugmakers Preparing To Take On Seasonal Flu With mRNA Technology

The [Wall Street Journal](#) (7/23, Roland, Subscription Publication) reported that Sanofi, GSK, and Pfizer are preparing to take on influenza with the same mRNA technology used in COVID-19 vaccines. Experts are hopeful mRNA technology could be a better fit to tackle quickly mutating flu strains than the currently used vaccines, which are often less than 60% effective.

## Drug Approvals



### FDA Approves Dalbavancin For Pediatric ABSSSI Treatment, Company Announces

[MedPage Today](#) (7/23, Walker) reported, “Antibiotic dalbavancin (Dalvance), previously approved to treat bacterial skin infections in adults, received FDA approval for the pediatric population from birth, manufacturer AbbVie” announced in a July 23 [press release](#). There, the drug “was described as the first single-dose option given as a 30-minute intravenous infusion to treat acute bacterial skin and skin structure infections (ABSSSIs) caused by designated susceptible Gram-positive bacteria, including those caused by methicillin-resistant *Staphylococcus aureus* (MRSA) in

pediatric patients.” The medication “is given as a single dose in pediatric patients with creatinine clearance of 30 mL/min/1.73 m<sup>2</sup> and above based on a patient’s age and weight.” [Healio](#) (7/23, Holland) also covered the approval.

### FDA Approves Once-Weekly Exenatide For Children With T2D

[Healio](#) (7/23, Schaffer) reported, “The FDA approved the GLP-1 receptor agonist exenatide for children aged 10 to 17 years with type 2 diabetes [T2D], the first once-weekly injectable approved for pediatric use in the United States, according to” a July 23 [press release](#) from AstraZeneca, maker of the drug. The agency’s “approval of exenatide extended release (Bydureon BCise, AstraZeneca) comes after positive phase 3 data” that “demonstrated adolescents with type 2 diabetes were more likely to achieve HbA1c targets after 24 weeks of once-weekly exenatide compared with placebo.” Click [here](#) to see more on this approval from the FDA. Providing similar coverage were [Clinical Endocrinology News](#) (7/23, Tucker) and [HCPlive](#) (7/23, Walter).

## Managed Care and Policy

### Several States Are Extending Health Insurance Coverage To Adult Immigrants Lacking Legal Status

An [AP](#) (7/24, Tareen) analysis said that Illinois “is among a handful of Democratic-run states extending health insurance coverage to adult immigrants in the country illegally, including seniors.” According to backers, the trend is critical amid “a coronavirus pandemic that has left immigrants, who are disproportionately essential workers, more vulnerable to COVID-19 and as federal remedies, like an immigration overhaul or ‘public option’ health insurance, face tough political odds.” The AP goes on to say, “Immigrants, both with legal status and without, are more likely to be uninsured than citizens.”

Meanwhile, [Axios](#) (7/24, Franco) reported, “Latino children in the U.S. are twice as likely to be uninsured as non-Latino children, according to an analysis by the Georgetown University Center for Children and

Families.” In excess of 1.8 million US Latino children have lacked “health insurance since before the pandemic, putting them at greater risk for COVID-19.” Axios added that the virus has impacted Latinos particularly severely, leading to “higher infection rates, hospitalizations and unemployment.”

## Friday's Lead Stories

- **Many Patients Being Billed For Preventive Care That Should Be Free, Study Shows**
- **FDA Says It Will Not Meet PDUFA Dates For Abrocitinib For Atopic Dermatitis And Tofacitinib For Active Ankylosing Spondylitis**
- **Benefits Of J&J COVID-19 Vaccine Outweigh Risks Of Guillain-Barré Syndrome, CDC Panel Says**
- **Study Finds Two Doses Of Pfizer, AstraZeneca COVID-19 Vaccines Almost As Effective Against Delta Variant As They Are Against Alpha Variant**
- **FDA Grants Regular Approval To Combination Of Pembrolizumab And Lenvatinib For Treatment Of Certain Women With Advanced Endometrial Carcinoma**
- **Uninsurance Rate Declines As Medicaid, ACA Marketplace Enrollment Rises, Report Shows**

### Subscriber Tools

- [Change Email Address](#)
- [Send Feedback](#)
- [Unsubscribe](#)
- [Email Help](#)
- [Archives](#)

Join AMCP

Renew Membership

Explore AMCP.org

Visit AMCP Meetings

AMCP Daily Dose is a digest of the most important news selected from thousands of sources by the editors of BulletinHealthcare. The Academy of Managed Care Pharmacy (AMCP) does not receive any revenue from the advertising herein. The presence of such advertising does not endorse, or imply endorsement of, any products or services by the AMCP.

This complimentary copy of *AMCP Daily Dose* was sent to [bwhitaker@amcp.org](mailto:bwhitaker@amcp.org) as part of your AMCP membership. Neither BulletinHealthcare nor the AMCP is liable for the use of or reliance on any information contained in this briefing.

Your personal data may be used to improve content delivery within this briefing.

Do not sell my personal information: if you have a do not sell my information request under the California Consumer Protection Act please go to our [CCPA Privacy Notice](#) to see how to contact us.

To see how we protect our data, or for any questions on data access, view BulletinHealthcare's [privacy policy](#) or [CCPA Privacy Notice](#).

For more information about AMCP, please contact AMCP's headquarters at 703-684-2600.

[Academy of Managed Care Pharmacy](#) | 675 North Washington Street, Suite 220, Alexandria, VA 22314

